In a report released today, Allan Franklin from Canaccord Genuity maintained a Buy rating on Experience Co Ltd (EXP – Research Report), with a ...

Canaccord Genuity analyst John Newman maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of ...

Doing it tough today was the Trump Tariff uncertainty crew. Those sectors that are likely to see earnings hits should ...

Given US bond and stock markets were closed Monday, and with few clear leads from major commodities markets overnight, there ...

DOUGLAS, ISLE OF MAN / ACCESS Newswire / January 30, 2025 / Agronomics (LSE:ANIC), a leading listed company in the field of clean food, is delighted to announce that its portfolio company, Liberation ...

With numerous day trading chart providers available in the market, choosing the right one can be a daunting task. To assist you in this endeavor, Benzinga has compiled a comparison list of some of ...

Canaccord said Science Group has an impressive and consistent track record of delivering a combination of organic and disciplined inorganic growth with minimal shareholder dilution. "This track ...

We continue our catch up of local and global indices, commodities, bonds and more in ChartWatch this evening with a look at the charts of ... Retained at sell at Canaccord Genuity; Price Target ...

Canaccord downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $74, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per ...

The move likely won’t have direct impact on most enterprise users, but indirect impact — which could be just as bad — is a definite possibility. Editor’s note: On Jan. 3, 2025, WordPress ...